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Abstract
A key task in cancer genomics research is to identify cancer driver genes. As these genes
initialise and progress cancer, understanding them is critical in designing effective cancer
interventions. Although there are several methods developed to discover cancer drivers,
most of them only identify coding drivers. However, non-coding RNAs can regulate driver
mutations to develop cancer. Hence, novel methods are required to reveal both coding and
non-coding cancer drivers. In this paper, we develop a novel framework named Controlla-
bility based Biological Network Analysis (CBNA) to uncover coding and non-coding cancer
drivers (i.e. miRNA cancer drivers). CBNA integrates different genomic data types, including
gene expression, gene network, mutation data, and contains a two-stage process: (1) Build-
ing a network for a condition (e.g. cancer condition) and (2) Identifying drivers. The applica-
tion of CBNA to the BRCA dataset demonstrates that it is more effective than the existing
methods in detecting coding cancer drivers. In addition, CBNA also predicts 17 miRNA driv-
ers for breast cancer. Some of these predicted miRNA drivers have been validated by litera-
ture and the rest can be good candidates for wet-lab validation. We further use CBNA to
detect subtype-specific cancer drivers and several predicted drivers have been confirmed
to be related to breast cancer subtypes. Another application of CBNA is to discover epithe-
lial-mesenchymal transition (EMT) drivers. Of the predicted EMT drivers, 7 coding and 6
miRNA drivers are in the known EMT gene lists.
Author summary
Cancer is a disease of cells in human body and it causes a high rate of deaths worldwide.
There has been evidence that coding and non-coding RNAs are key players in the initiali-
sation and progression of cancer. These coding and non-coding RNAs are considered as
cancer drivers. To design better diagnostic and therapeutic plans for cancer patients, we
need to know the roles of cancer drivers in cancer development as well as their regulatory







Citation: Pham VVH, Liu L, Bracken CP, Goodall
GJ, Long Q, Li J, et al. (2019) CBNA: A control
theory based method for identifying coding and
non-coding cancer drivers. PLoS Comput Biol
15(12): e1007538. https://doi.org/10.1371/journal.
pcbi.1007538
Editor: Ilya Ioshikhes, Ottawa University, CANADA
Received: April 25, 2019
Accepted: November 12, 2019
Published: December 2, 2019
Copyright: © 2019 Pham et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All the datasets used
in this paper are available at https://github.com/
pvvhoang/CancerDriver.
Funding: This work has been supported by the
NHMRC Grant (No: 1123042), the Australian
Research Council Discovery Grant (No:
DP170101306), and Australian Government
Research Training Program (RTP) Scholarship.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
mechanisms in the human body. In this study, we propose a novel framework to identify
coding and non-coding cancer drivers (i.e. miRNA cancer drivers). The proposed frame-
work is applied to the breast cancer dataset for identifying drivers of breast cancer.
Comparing our method with existing methods in predicting coding cancer drivers, our
method shows a better performance. Several miRNA cancer drivers predicted by our
method have already been validated by literature. The predicted cancer drivers by our
method could be a potential source for further wet-lab experiments to discover the causes
of cancer. In addition, the proposed method can be used to detect drivers of cancer sub-
types and drivers of the epithelial-mesenchymal transition in cancer.
Introduction
As cancer driver genes (cancer drivers for short) play significant roles in cancer development
and progression, identifying cancer drivers and their regulatory mechanism is critical in the
design of effective cancer treatments. There has been evidence that cancer drivers are related
to gene mutations. Mutations in the genome can be single-nucleotide variants (SNVs), inser-
tions and deletions (indels), copy number aberrations (CNAs), or structural variants (SVs) [1].
These mutations might cause normal cells to transform to tumour cells, resulting in cancer
initialisation and development. For instance, it has been confirmed that the mutations in
AKT1 and BRCA1 genes cause breast cancer [2] and the mutations in MET and VHL genes
are related to kidney cancer [3]. Nevertheless, some mutations might not progress cancer.
Mutations which have impacts on cancer development are driver mutations while mutations
which do not play any role in cancer development are passenger mutations [4, 5]. Genes that
bear driver mutations are considered as cancer drivers [6]. However, some genes, which do
not bear mutations but do regulate driver mutations to progress cancer, are also considered as
cancer drivers as shown in Fig 1. Moreover, cancer drivers can also be non-coding RNAs since
non-coding regions account for around ninety eight percent of the human genome [7] and
non-coding RNAs are proved to be related to cancer development [8, 9].
Fig 1. Coding cancer drivers and genes with mutations. Genes with driver mutations are cancer drivers. Some genes which do not
bear mutations but regulate driver mutations to progress cancer are also considered as cancer drivers.
https://doi.org/10.1371/journal.pcbi.1007538.g001
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A wide range of computational methods utilising various types of genomic data have been
developed to identify cancer drivers and their regulatory mechanisms behind the cancer initia-
lisation and progression. In general, these computational methods can be categorised into two
main approaches: mutation-based approach and network-based approach. Mutation-based
approach includes methods which classify driver mutations and passenger mutations mainly
based on mutations and their characteristics, i.e. functional impact [10], recurrence [11–14],
enrichment in externally defined regions [15], mutual exclusivity [4, 16], etc. Particularly,
OncodriveFM [10] evaluates the functional impacts of gene mutations to discover cancer driv-
ers based on the hypothesis that genes which have a variation with significantly functional
impacts can be candidate driver genes. OncodriveCLUST [11] hypothesises that gain-of-func-
tion mutations largely cluster in particular protein sections and the proposed method reveals
cancer driver genes whose mutation clustering is largely biased. ActiveDriver [15] discovers
driver genes which are enriched in mutations located in post-translationally modified sites.
WeSME [16] and CoMEt [4] identify cancer driver genes by utilising statistical tests to evaluate
the mutual exclusivity of genomic events and candidate cancer drivers are genes which have
mutations with a significantly mutual exclusivity. One more example in the mutation-based
approach is CHASM [17], which applies random forest, a machine learning technique, to
detect driver mutations.
The second main approach includes network-based methods which identify cancer drivers
by evaluating the role of genes in a biological network [18–24]. A typical method in this cate-
gory is DawnRank [18], a ranking framework that applies PageRank [25, 26] to assess the
impact of genes in a gene interaction network. DriverNet [19] integrates an influence graph,
genome data, and transcriptome data to detect driver genes. Like WeSME [16] and CoMEt
[4], MEMo [20] also relies on the mutual exclusivity of mutations but the method combines
the mutation information with network information to identify mutual exclusivity modules in
networks. TieDIE [21] applies network diffusion to detect cancer drivers based on the relation-
ship of genomic events and changes in cancer subtypes. iMCMC [22] uses network informa-
tion to identify mutated core modules in cancer.
The two types of methods have their own advantages and limitations. Mutation-based
methods are easy to be applied to different mutation datasets as they are mainly based on
mutation data. However, their applications are limited due to the incompleteness of mutation
databases. Network-based methods are able to elucidate molecular mechanisms in developing
diseases at the network level [27, 28], but they usually require large datasets to generate reliable
results. Furthermore, most current methods use general networks which are not specific to
any cancer type. Thus, these networks might include some interactions which do not exist in a
certain cancer type. Another potential limitation of network-based methods such as Dawn-
Rank and DriverNet is that they discover only candidate drivers which alter other genes’
expression. However, some drivers may not change other genes’ expression, or some genes
accidentally alter other genes’ expression although they are not drivers. In addition, current
methods detect coding drivers though cancer drivers can also be non-coding RNAs. Therefore,
there is a strong need for effective methods to find both coding and non-coding drivers and
their regulatory relationships that drive cancers.
With the aim to detect both coding and non-coding drivers, in particular microRNA
(miRNA) drivers, we develop a novel and effective method called Controllability based Biolog-
ical Network Analysis (CBNA). We firstly build the network for a condition (e.g. cancer state)
from the expression data of miRNAs, Transcription Factors (TFs), and mRNAs of cancer
patients. We then combine this network with the protein-protein interaction (PPI) network
[29] and filter out edges of the network learned from the expression data, which are not in
existing databases, including miRTarBase [30], TarBase [31], miRWalk [32], TargetScan [33],
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and TransmiR [34]. Besides integrating miRNAs into the network, we utilise the gene expres-
sion of patient cohort in building it. Thus, we eliminate interactions which do not exist in a
particular cancer type and the resulting network is specific to that cancer type. We will then
discover drivers based on the network.
To overcome the limitation of the current methods which are based on the effect of poten-
tial drivers on downstream genes’ expression in the network as the above discussion, we might
need to have a more effective method to evaluate the role of genes in the network. Inspired by
control theory [35] and its application in detecting a subset of nodes in a network which can
control the whole network [36], we apply them to analyse the above network. Control theory
has a wide range of applications, from electric circuits or manufacturing processes to space-
craft or robots. According to control theory, a system is controllable if we can drive it from any
state to any expected state in a time frame by suitable inputs. Based on control theory, the idea
of network control was introduced in [36] to capture the state of how a subset of nodes in a
network, known as critical nodes, control the whole network at a time. Following this idea, we
apply the method in [36] to identify the critical nodes in the network learned above. We con-
sider the critical nodes as the driver genes in the network as they play the central roles in the
network of cancer state and likely control that cancer condition. Finally, we use the mutation
data (i.e. somatic mutations) to compute mutation frequency of genes to rank the predicted
cancer drivers.
We apply the proposed method to the breast invasive carcinoma (BRCA) dataset of The
Cancer Genome Atlas (TCGA) [37] to identify breast cancer drivers. The predicted breast
cancer drivers include coding drivers with mutations, coding drivers without mutations, and
miRNA drivers. We validate the coding drivers with mutations using Cancer Gene Census
(CGC) [38] and the result shows that the proposed method outperforms the existing methods,
including OncodriveFM [10], OncodriveCLUST [11], ActiveDriver [15], DawnRank [18], Dri-
verNet [19], and NetSig [39]. Several predicted coding drivers without mutations are enriched
in molecular functions and biological processes, suggesting their important roles in the human
body and the effectiveness of the method. Moreover, we discover 17 miRNA drivers for breast
cancer, some of which have been validated by literature and the rest can be good candidates
for wet-lab validation.
We go further to study subtype-specific drivers by comparing the controllability of net-
works of different cancer subtypes. We predict several drivers which are specific to breast can-
cer subtypes as well as some genes which drive more than one subtype. In addition, we also
apply CBNA to detect drivers of epithelial-mesenchymal transition (EMT) [40] and some dis-
covered drivers are mesenchymal genes [41] or pro-mesenchymal miRNAs [42]. These results
demostrate that CBNA is useful not only in identifying cancer drivers but also in predicting
drivers for other processes such as EMT. Thus, CBNA provides a promising framework to
study molecular mechanisms of the development of cancer and other diseases.
Materials and methods
Materials
In this project, we apply the proposed method CBNA to the BRCA dataset of TCGA [37]. This
dataset contains the expression data of miRNAs, TFs, and mRNAs of 747 samples. The TF list,
which is used to find which genes are TF genes in the expression dataset, is obtained from the
work of [43]. CBNA also employs the directed PPI network of [29]. Besides, the method uses
various databases of miRNA-TF and miRNA-mRNA interactions, including miRTarBase ver-
sion 6.1 [30], TarBase version 7.0 [31], miRWalk version 2.0 [32], TargetScan version 7.0 [33],
and a database for TF-miRNA interactions, TransmiR version 2.0 [34]. The mutation data in
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this study is also acquired from TCGA. All the datasets used in this paper are available at
https://github.com/pvvhoang/CancerDriver.
Controllability based Biological Network Analysis (CBNA)
Overview. As shown in Fig 2, CBNA has two stages: (1) Building the network for a condi-
tion, and (2) Identifying coding and miRNA drivers. The detail of CBNA is described in the
following sections.
Identifying cancer drivers with controllability analysis.
1. Building the network for a condition
At the first stage, CBNA builds the network for a condition in three steps as described in
the following.
• Step 1a: Prepare the expression data of miRNAs, TFs, and mRNAs. We extract the expres-
sion data of matched samples of miRNAs and coding genes from the BRCA dataset [37].
In total, 747 samples are obtained. As the number of coding genes are over twenty thou-
sand, we only select coding genes which are in the PPI network [29]. We then use the TF
list in [43] to categorise the coding genes into two subsets, TFs and mRNAs. Finally, we
have the expression data of 1,719 miRNAs, 839 TFs, and 5,168 mRNAs.
• Step 1b: Build the miRNA-TF-mRNA network. We build the miRNA-TF-mRNA network
for cancer state based on the above expression data. We firstly identify all pairwise Pearson
[44] correlation coefficients (PCC) of all the nodes. We then calculate the significance of
PCCs and apply an FDR cutoff (i.e. 0.05) to retain edges whose adjusted p-value is less
Fig 2. An illustration of CBNA. (1) Building the network for a condition: (a) Prepare matched miRNA and TF/mRNA expression
data, (b) Build miRNA-TF-mRNA network where nodes represent miRNAs/TFs/mRNAs and an edge between two nodes indicates
there is a significant Pearson correlation between the expression of the two nodes, (c) Create the network by combining the
miRNA-TF-mRNA network with the PPI network and other existing databases, and (2) Identifying coding and miRNA drivers: (a)
Detect critical nodes, (b) Identify candidate cancer drivers.
https://doi.org/10.1371/journal.pcbi.1007538.g002
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than 0.05. The directions of the edges are determined as shown in Fig 3. In particular, miR-
NAs can regulate TFs & mRNAs, TFs can regulate miRNAs & mRNAs, and TFs/mRNAs
can regulate other TFs/mRNAs.
• Step 1c: Create the condition-specific network. To retain the ‘true’ interactions of coding
genes, we firstly update the miRNA-TF-mRNA network with the PPI network by remov-
ing the edges between coding genes which are not in the PPI network. The PPI network is
selected as it is a directed network, thus it can be used to combine with the directed miR-
NA-TF-mRNA network built in Step 1b. We then refine the obtained network by remov-
ing the edges if they are not in databases miRTarBase, TarBase, miRWalk, TargetScan, or
TransmiR. As the network is obtained based on both expression data and existing data-
bases, it is more reliable and specific to a certain cancer type. The final cancer condition-
specific network consists of 7,726 nodes (including 1,719 miRNAs, 839 TFs, and 5,168
mRNAs) and 128,264 edges (inlcuding 16,087 miRNA-TF edges, 73,347 miRNA-mRNA
edges, 18,950 TF-miRNA edges, 1,812 TF-TF edges, 1,188 TF-mRNA edges, and 16,880
mRNA-mRNA edges).
As the motif shown in Fig 3, TF-TF/mRNA and mRNA-mRNA interactions of the miR-
NA-TF-mRNA network from Step 1b are refined with the PPI network. miRNA-TF/
mRNA interactions are refined with miRTarBase, TarBase, miRWalk, TargetScan and TF-
miRNA interactions are refined with TransmiR.
Fig 3. Determining the directions of edges in the miRNA-TF-mRNA regulatory network. In a miRNA-TF-mRNA regulatory
network, miRNAs can regulate TFs and mRNAs, TFs can regulate miRNAs and mRNAs, TFs/mRNAs can regulate other TFs/
mRNAs. This motif is adapted from the work of [66]. In addition, the databases used to filter out edges of the network are shown on
arrows.
https://doi.org/10.1371/journal.pcbi.1007538.g003
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2. Identifying coding and miRNA drivers
At the second stage, CBNA identifies drivers from the built network with the following two
steps.
• Step 2a: Detect critical nodes of the built network. According to the network control idea [36]
(Details are introduced in the next section), a network can be fully controlled by a minimum
set of nodes called minimum driver node set (MDNS). Applying this network control idea,
we detect the MDNS of the network obtained from stage 1. Then we discover critical nodes
of the network. The critical nodes are nodes whose absence causes a rise in the size of the
MDNS. It means that when these critical nodes are removed from the network, more interac-
tions on nodes (i.e. interactions on driver nodes) are needed to control the whole network.
• Step 2b: Identify candidate cancer drivers. As without the critical nodes, we need to inter-
act on more driver nodes to control the whole regulatory network, the critical nodes play
the central role in controlling the whole network and alterations in these nodes such as
over expression or mutation might transform the state of a person from normal to cancer.
Thus, these critical nodes in the network obtained from Stage 1 can be considered as can-
didate cancer drivers. We categorise the candidate cancer drivers into three subsets, coding
drivers with mutations, coding drivers without mutations, and miRNA drivers. As most of
the predicted drivers are coding drivers with mutations, we rank predicted coding drivers
with mutations to get significant candidates. We download the mutation data of the BRCA
samples from TCGA. Based on the variant classification of mutations, we only select muta-
tions which are functional, such as splice_site, in_frame_del, frame_shift_del, etc. and
compute the mutation frequency of coding genes. The more frequent the mutation of a
coding driver is, the higher it is in the ranking list.
Controllability of complex networks. The idea of the network control [36] is that a
directed network can be guided by a subset of nodes known as driver nodes. The mathematical
theory behind this network control idea is described as below.
Suppose that we have a system with N nodes x1, . . ., xN. The following NxN matrix A cap-
tures the interaction strength between nodes:
A ¼
a11 a12 � � � a1N


















where aij represents the edge strength of node j on node i (i, j 2 {1, . . ., N}). If there is no edge
from node j to node i then aij = 0.
Let BN×M be the input matrix (M� N) which indicates M nodes controlled by an external
controller:
B ¼
b1 0 � � � 0




































where bi represents the interaction strength of the controller on node i (i 2 {1, . . ., M}).
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Based on Kalman’s controllability condition [35], the network represented by the matrix A
is controllable through the M nodes indicated in B (these M nodes are called driver nodes) if
and only if the controllability matrix CN×NM satisfies the following:
rankðCÞ ¼ N; ð3Þ
where C is a combination of matrices B, AB, A2B, . . ., AN−1B and represented as C = (B, AB,
A2B, . . ., AN−1B).
Intuitively, the rank of the controllability matrix C being N indicates that all N variables (i.e.
N nodes of the network) are controllable. In addition, it can be noted that as we just need to
identify the rank of C, we do not need to compute the value of C. The condition shown in Eq
(3) can be satisfied if it is possible to select non-zero link weights in A and B. Therefore, this
method can also be applied to networks without the weight of links among nodes.
We may identify several sets of nodes which can satisfy the condition Eq (3). However, we
are interested in discovering the minimum number of driver nodes (i.e. minimum M), called
minimum driver node set (MDNS), whose control is sufficient to control the whole network.
In step 2a of the second stage of CBNA, applying this method, we identify the MDNS of the
miRNA-TF-mRNA network. Then we detect critical nodes for our network by removing node
by node out of the network, if the absence of a node increases the size of the MDNS, it is a criti-
cal node.
Using the network control, our method can discover driver genes which are coding RNAs
without mutations or miRNAs, which are missed by other cancer driver identification meth-
ods. In addition, since our method allows to build the network based on the expression data, it
can be applied to detect drivers for any condition or disease other than cancer drivers.
Implementation. The proposed framework has been developed in R and its source code
as well as the scripts for reproducing the experiment results in this study are available at
https://github.com/pvvhoang/CancerDriver.
Results and discussion
Characterising the controllability of the miRNA-TF-mRNA network
The miRNA-TF-mRNA network obtained by CBNA consists of 7,726 nodes and 128,264
directed edges. We apply the method in [36] to evaluate the controllability of the network by
identifying its MDNS. Although the MDNS is not unique, all the MDNS sets identified in the
BRCA network are of the same size (i.e. contain the same number of nodes, denoted as ND).
The identified MDNS contains 2,877 nodes (i.e. ND is 2,877), accounting for 39.1% of the
nodes in the constructed miRNA-TF-mRNA network. We then classify the nodes in the miR-
NA-TF-mRNA network as critical, ordinary, and redundant based on the change of ND upon
their removal. A node is critical if its removal increases ND, ordinary if removing it does not
change ND, and redundant if removing it decreases ND. In the miRNA-TF-mRNA network,
13.3% of nodes are critical, 47.4% are ordinary, and the remaining 39.3% are redundant (Fig
4A). We find that critical nodes have higher in-degrees compared with ordinary and redun-
dant nodes, which can be seen in the average in-degree and accumulative in-degree distribu-
tions of nodes in Fig 4B. From Fig 4C, the out-degrees of critical nodes are high, although
ordinary nodes have higher out-degrees.
CBNA is effective in detecting coding cancer drivers with mutations
In this section, we compare the performance of the proposed method CBNA with six
existing methods for identifying cancer drivers, OncodriveCLUST [11], ActiveDriver [15],
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OncodriveFM [10], DriverNet [19], DawnRank [18], and NetSig [39]. As these methods are
developed to discover coding cancer drivers, we only compare these six methods with CBNA
in discovering mutated coding cancer drivers. These methods are selected as they are represen-
tatives of different approaches for uncovering cancer drivers. OncodriveCLUST, ActiveDriver,
and OncodriveFM are mutation-based methods while DriverNet, DawnRank, and NetSig are
network-based methods. OncodriveCLUST deals with the clustering of mutations in genes,
ActiveDriver detects enrichment of mutated genes in externally defined regions, and Oncodri-
veFM evaluates the functional impacts of mutations. For the three network-based methods,
DriverNet combines an influence graph with genome data and transcriptome data to discover
driver genes, DawnRank applies PageRank to rank the impact of genes in the network, and
NetSig integrates protein interaction networks and tumour data to predict driver genes. Since
these methods have different assumptions for identifying cancer drivers, each method may
miss some particular driver genes. For example, OncodriveCLUST would miss tumour genes
with broad mutation patterns as it is based on the clustering of mutations and DawnRank
would miss some drivers which do not alter the expression of other genes as it uses the impact
of genes.
For the experiments in this paper, we use the BRCA dataset of TCGA [37], including the
expression data and the mutation data. For the interaction network required by DriverNet, we
Fig 4. Characterising the controllability of the miRNA-TF-mRNA network. (A) Identification of critical, ordinary, and redundant
nodes in the network. (B) Average in-degree and accumulative in-degree distribution (i.e. the in-degree i with the probability p
means that the probability to pick a node which has in-degree larger than or equal to i is p) for three different node types. (C)
Average out-degree and accumulative out-degree distribution for three different node types.
https://doi.org/10.1371/journal.pcbi.1007538.g004
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use the network from the paper [45]. The network used by DawnRank in our experiments is
obtained directly from the authors of the method [18]. The network used by our proposed
method CBNA is described in Section Materials and methods.
We utilise the Cancer Gene Census (CGC) from the COSMIC database [46] as a ground-
truth for coding driver genes. CGC is a commonly used cancer gene database in cancer
research for validating cancer drivers predicted by computational methods. We measure per-
formance of a method based on the number of uncovered cancer driver genes which are in
CGC. The higher the number of validated cancer driver genes a method has discovered, the
better the method is.
To facilitate the comparison, the top cancer driver genes (top 50, 100, 150, and 200 respec-
tively) predicted by each of the seven methods are chosen to be validated with the CGC.
OncodriveCLUST, OncodriveFM, and NetSig order their discovered cancer driver genes
based on a corrected p-value. The results of ActiveDriver and DriverNet are ordered by p-
value. The cancer drivers predicted by DawnRank are sorted by the ranking scores used by
the method, and the ranking of identified cancer drivers by CBNA is based on the mutation
frequency of genes.
The result of the comparison is shown in Fig 5. In the case of the top 50 cancer drivers pre-
dicted by the methods, the CBNA is comparable to OncodriveFM and they outperform the
other five methods. In the cases of top 100, 150, and 200 discovered driver genes, CBNA out-
performs the other given methods. In addition, instead of ranking predicted coding cancer
drivers based on the mutation frequency of genes, we also rank predicted genes based on
mutation frequency and spectrum of patients, mutation rates of genes incorporating
Fig 5. Validation using CGC. The cancer drivers predicted by each method are validated against CGC. Each bar in the chart
indicates the number of validated coding driver genes for each method.
https://doi.org/10.1371/journal.pcbi.1007538.g005
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expression level and replication time, and functional impact of mutations (see the detail in
Supplementary section 1 in S1 Text).
To have a more comprehensive comparison, we also use the following three measures, Pre-
cision, Recall, and F1 Score computed based on CGC and the top N genes (N is from 1 to 200)













where tp represents the number of discovered cancer drivers which are in CGC, fp is the num-
ber of discovered cancer drivers which are not in CGC, and fn is the number of drivers which
are in CGC but not discovered by the method.
The comparison result is shown in Fig 6. We see that although OncodriveFM has better or
similar performance as CBNA when N is small, our method outperforms OncodriveFM and
the other five methods when N becomes larger.
In the above evaluation, we looked at the top cancer driver genes predicted by the methods,
now we evaluate the methods based on the total number of driver genes predicted by the meth-
ods, in the same way as the evaluation done by the study in [6]. The detailed result is shown
in Fig 7, where we see that the total numbers of predicted drivers vary (q� 0.1 for Oncodrive-
CLUST and OncodriveFM (q-value is the corrected p-value), p� 0.05 for ActiveDriver and
DriverNet, adjusted p�0.05 for NetSig, all predicted genes by DawnRank and CBNA). Active-
Driver, DawnRank, NetSig, and CBNA predict around or over 500 driver genes, whereas the
remaining has less than 500 genes. For each method, using CGC, we assess the fraction of vali-
dated driver genes among all the driver genes predicted by the method, and as shown in Fig 7B
CBNA has the highest number of validated driver genes comparing to the other six methods.
Although CBNA outperforms other current benchmark methods in identifying cancer
drivers, computational methods may never completely replace wet-lab experiments in validat-
ing the biological findings. However, the novel cancer drivers predicted by CBNA can be good
candidates for further wet-lab experiments to confirm their roles in cancer initialisation and
progression. As we construct the network using PCCs, the expression levels of a gene may not
matter but the correlation of the expression levels of two genes matters. In saying so, including
Fig 6. Comparison of Precision, Recall, and F1Score for the top ranking genes predicted by OncodriveCLUST, ActiveDriver,
OncodriveFM, DriverNet, DawnRank, NetSig, and CBNA. In each diagram, the x-axis is the number of the top ranking genes. The
y-axis is the value of Precision, Recall, or F1 Score.
https://doi.org/10.1371/journal.pcbi.1007538.g006
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many lowly-expressed genes may cause false positives, and thus we provide an option pre-pro-
cessing function to filter out those genes before applying CBNA to the dataset to identify can-
cer drivers.
To evaluate the impact of the adjusted p-value cutoff on the performance of CBNA, we run
CBNA with different cutoff values and the results are shown in Fig 8. It can be seen that the
performance of CBNA is quite consistent in different settings. It does not change much when
we change the adjusted p-value thresholds.
In addition, to check if the selected network-based methods detect similar cancer drivers,
we compare their results and the findings of the four methods have little overlap as indicated
in Fig 9. In the figure, the top 50, 100, 150, and 200 cancer driver genes identified by these
methods and validated against the CGC are intersected. Although there are some known can-
cer drivers uncovered by multiple methods, CBNA discovers some important known cancer
drivers which are not identified by others. Since the results of these methods are complemen-
tary, they could be used together to maximize the effectiveness in predicting cancer drivers.
Moreover, besides the known cancer drivers in the CGC, CBNA can detect novel cancer driv-
ers which can be used as candidates in wet-lab experiments to confirm their roles in the cancer
initialisation and progression.
To further evaluate the performance of network-based methods in detecting breast cancer
drivers, we validate the coding cancer drivers by these methods against a well-curated set of
Fig 7. Evaluation based on the total number of predicted driver genes. (A) Number of predicted drivers, (B) Fraction of validated
drivers in the CGC and raw count of predicted drivers indicated on top of each bar.
https://doi.org/10.1371/journal.pcbi.1007538.g007
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breast cancer drivers obtained from [38], [47], [2], and [48] (see the breakdown of the known
breast cancer driver genes in Supplementary section 2 in S1 Text). The result of the validation
is shown in Fig 10. From Fig 10, in the cases of the top 50 and top 100 predicted cancer drivers,
CBNA outperforms all the other three methods. In the cases of the top 150 and top 200 pre-
dicted cancer drivers, CBNA still outperforms DriverNet and DawnRank and has similar or
slightly lower performance compared to NetSig.
Ranking mutated coding drivers predicted by CBNA based on mutation
density
Although CBNA outperforms other the existing methods in identifying mutated coding cancer
drivers, it contains false positive drivers, whose mutation frequency is high, due to their length
such as TTN and DMD. Thus, to eliminate these long genes out of the top hits, we have imple-
meted another option to rank predicted mutated cancer drivers based on mutation density
(i.e. the ratio of mutation count and gene length). The top 20 mutated coding drivers using
mutation density are listed in Table 1.
Discovering coding cancer drivers without mutations and miRNA cancer
drivers
The percentage of coding and miRNA cancer drivers uncovered by CBNA is presented in Fig
11. In addition to discovering coding cancer drivers with mutations, CBNA also has the ability
to identify coding cancer drivers without mutations and miRNA cancer drivers (see the list of
Fig 8. CBNA using different adjusted p-value cutoffs. The cancer drivers predicted by CBNA with different adjusted p-value
cutoffs are validated by the CGC. Each bar in the figure shows the number of validated coding cancer drivers of CBNA with a cutoff.
https://doi.org/10.1371/journal.pcbi.1007538.g008
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coding drivers without mutations in S2 Table and list of miRNA drivers in S3 Table). It can be
seen from Fig 11 that only 1.6% of drivers predicted by CBNA are miRNA drivers. One of the
reasons is that the number of coding genes in the network used by CBNA is much more than
the number of miRNAs. In addition, as illustrated in Fig 2, candidate drivers play the central
roles in the network rather than only regulating other nodes (i.e. a gene/node which has more
incoming and outgoing edges in the network has higher chance to be a driver gene). However,
miRNAs do not have high enough incoming edges as they regulate TFs and mRNAs, but only
a small amount of miRNAs are regulated by TFs.
Most of the coding candidate drivers without mutations are novel drivers since the existing
methods are not designed for finding drivers without mutations. As a result of lacking ground-
truth, we use GO [49] enrichment analysis for the evaluation of CBNA in detecting coding
cancer drivers without mutations (see the detail of the enrichment analysis in Supplementary
section 3 in S1 Text). The enrichment analysis shows that several predicted drivers are signifi-
cantly associated with enriched terms in GO biological process and GO molecular function,
suggesting that the findings of our method are biologically meaningful. Among the top pre-
dicted coding drivers involved in GO biological process and molecular function, CDC42 is the
most promising potential cancer driver. There has been evidence that CDC42 plays a critical
role in promoting breast cancer cell invasion and forming invadopodia by activating N-WASp
[50]. This gene is enriched in many GO terms, including nucleoside-triphosphatase activity,
purine ribonucleoside binding, guanyl ribonucleotide binding, etc. Other drivers predicted by
our method, including IRS2 and SUMO2, have been shown by previous studies [51, 52] to be
related to breast cancer.
Fig 9. Overlap between different methods. The diagram shows the overlap among the four methods in their top 50, 100, 150, and
200 predicted drivers. For each of the four cases, the horizontal bars at the bottom left show the numbers of predicted cancer drivers
validated by the CGC for the four methods; the vertical bars and the dotted lines together indicate the numbers of validated cancer
drivers which overlap with each other.
https://doi.org/10.1371/journal.pcbi.1007538.g009
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Table 1. The top 20 mutated coding drivers using mutation density.
No. Predicted driver Mutation density In CGC?
1 TP53 0.0127275 ✓
2 PIK3CA 0.0041422 ✓













16 HLA-A 0.0010813 ✓
17 HSPA8 0.0010451




Fig 10. Validation using a well-curated set of breast cancer drivers. The cancer drivers predicted by the methods are validated by a
well-curated set of breast cancer drivers. Each bar in the figure shows the number of validated coding cancer drivers of each method.
https://doi.org/10.1371/journal.pcbi.1007538.g010
Identifying coding and non-coding cancer drivers
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007538 December 2, 2019 15 / 23
CBNA also identifies 17 potential miRNA cancer drivers. Eleven of them have been con-
firmed as miRNAs related to tumorigenesis of BRCA by OncomiR [53], a resource for study-
ing pan-cancer miRNA dysregulation. Especially, among these 11 miRNAs, hsa-miR-342-5p
has been proved to be involved in progressing breast cancer in another work [54]. According
to [54], hsa-miR-342-5p is a regulator of the growth of breast cancer cells. Besides, other miR-
NAs predicted by CBNA are also potential drivers, such as hsa-miR-130a-5p and hsa-miR-223-
5p. hsa-miR-130a-5p targets FOSL and upregulates ZO-1 in order to suppress breast cancer cell
migration [55] and hsa-miR-223-5p is a coordinator of breast cancer [56]. The summary of
predicted miRNA BRCA drivers is shown in Table 2.
Identifying drivers in different conditions
Since the biological condition of cancer patients is different from that of healthy people, the
important genes in cancer and non-cancer condition might be different. It means that some
genes become critical in the cancer condition while they are of little importance in the normal
condition. We concern these genes as they are specific for the tumour state. Hence, we system-
atically analyse driver genes which are particular for the cancer condition only. Due to the fact
Fig 11. Identification of coding and miRNA cancer drivers. The chart shows the percentage of different types of
cancer drivers identified by CBNA from the BRCA dataset.
https://doi.org/10.1371/journal.pcbi.1007538.g011
Identifying coding and non-coding cancer drivers
PLOS Computational Biology | https://doi.org/10.1371/journal.pcbi.1007538 December 2, 2019 16 / 23
that CBNA can identify drivers for a network in a condition, we apply CBNA to detect regula-
tors in the normal condition. Specifically, instead of using the expression data of breast cancer
patients, we use the expression data of normal samples to build the network (see the detail of
the network in Supplementary section 4 in S1 Text). The drivers identified by CBNA based on
this network are regulatory genes in the normal condition. Then we compare them to the
driver genes of the cancer condition to uncover cancer drivers which are only specific to the
cancer state. As in this approach, there are few coding drivers without mutations and miRNA
drivers are similar to those in the original approach, we only focus on coding drivers with
mutations. We validate these predicted coding cancer drivers with mutations (i.e. only specific
to cancer condition) against the CGC and there are 45 validated drivers (see the list of these 45
drivers in S4 Table).
Exploring drivers for cancer subtypes
As breast cancer has several subtypes with different morphologies and clinical outcomes, the
subtypes might have different causes and drivers. In this section, we explore candidate drivers
for breast cancer subtypes using CBNA. Firstly, we categorise the 747 breast cancer samples
into different subtypes using the Pam50 method [57, 58]. As a result, we have 221 samples in
Luminal A subtype, 165 samples in Luminal B subtype, 158 samples in Basal subtype, 108 sam-
ples in Her2 subtype, and 95 samples in Normal-like subtype. Then, we apply CBNA to these
subsets respectively in order to identify drivers for each subtype of breast cancer. The predicted
drivers which are specific to only one subtype of breast cancer are listed in Table 3.
To obtain the list of predicted drivers, we use the subtype-specific mutations to rank the
candidate drivers and for each subtype, only those candidate drivers which have dominant
mutations in that subtype are included in the list of predicted drivers. Mutations of a gene are
dominant in a subtype if they belongs to that subtype more than to all other subtypes. It has
been shown that some promising subtype-specific cancer drivers predicted by CBNA are
PTEN (Luminal A) and FN1 (Luminal B). Luminal A tumours have a strong and diffuse
Table 2. miRNA BRCA drivers predicted by CBNA.
No. Predicted driver Confirmed References
1 hsa-miR-130a-5p ✓ [55]
2 hsa-miR-141-5p ✓ [53]
3 hsa-miR-142-5p ✓ [53]
4 hsa-miR-181a-5p ✓ [53]
5 hsa-miR-214-5p ✓ [53]
6 hsa-miR-222-5p
7 hsa-miR-223-5p ✓ [56]
8 hsa-miR-23a-5p ✓ [53]
9 hsa-miR-338-5p ✓ [53]
10 hsa-miR-342-5p ✓ [53, 54]
11 hsa-miR-3614-5p ✓ [53]
12 hsa-miR-3648 ✓ [53]




17 hsa-miR-9-5p ✓ [53]
https://doi.org/10.1371/journal.pcbi.1007538.t002
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expression of PTEN [59] and FN1 plays pivotal roles in the tumorigenesis of Luminal B breast
cancer by influencing the pathways in cancer [60].
Detecting drivers of epithelial-mesenchymal transition
Metastasis, a migration process of cancer cells from the primary tumour, mainly causes the
death of cancer patients. One process which creates these metastatic cells is epithelial-mesen-
chymal transition (EMT) [61]. There is evidence that EMT is promoted by coding RNAs
[62] and/or non-coding RNAs [63]. Thus, in this section, we apply our proposed method to
the BRCA dataset to detect drivers for breast cancer metastasis. Since our method identifies
driver genes which control the mesenchymal condition, the identified driver genes are
expected to drive the transition from epithelial state to mesenchymal state in breast cancer
patients.
We firstly classify the 747 breast cancer samples into different phenotypes by using EMT
score [41]. As a result, we have 189 epithelial samples, 461 mesenchymal samples, 44 interme-
diately epithelial samples, and 53 intermediately mesenchymal samples. We then apply CBNA
to the 461 mesenchymal samples to build the network for the mesenchymal condition and dis-
cover drivers which cause this mesenchymal condition. Say in other words, these predicted
drivers, called EMT drivers, regulate the transition from epithelial to mesenchymal.
We validate the top 100 predicted coding EMT drivers against mesenchymal genes in EMT
signatures [41] and 17 predicted miRNA EMT drivers against pro-mesenchymal miRNAs in
EMT miRNAs [42]. There are 7 validated coding and 6 validated miRNA drivers. The p-values
of these overlaps between the predicted drivers and EMT genes/EMT miRNAs are significant
at 0.007 and 1.333e-07 respectively (see the detail of epithelial-mesenchymal transition drivers
in Supplementary section 5 in S1 Text).
There are several potential EMT drivers which are predicted by our method, such as FYN,
E2F1, and EP300. FYN promotes mesenchymal phenotypes through STAT5/NOTCH2 signal-
ling node in Basal breast cancer cells [62]. E2F1 drives epithelial-mesenchymal transition by
regulating TXNIP [64]. The downregulation of EP300 is related to the initiation of an EMT
Table 3. Predicted drivers which are specific to each breast cancer subtype.
Subtype Coding drivers with mutations
(Top 10)
Coding drivers without mutations miRNA drivers
Luminal
A
PTEN, RUNX1, MED12, ATM,
DSP, SF3B1, ATXN2, CHD3, HTT,
NCOA6
ADAM17, APEH, ARF6, AVP, AVPR1A, BARX1, BTBD2,
CAMLG, CSF2, DLEU1, EXOSC6, F2RL3, GADD45A,
HBEGF, HLA-DRA, IFNGR2, MMP7, PAFAH1B2,
PPP1R9B, RNF216, RNF7, RPS27A, SOX4, STMN2,
TGOLN2, TNFRSF13C, WASH2P
hsa-let-7i-5p, hsa-miR-130a-5p, hsa-miR-181a-5p, hsa-




GATA3, ERBB2, TAF1, HDAC6,
SETDB1, DLG1, EP400, UBC,
ARHGEF12, FN1
ARF3, DCP1A, IL2, POMC, RAB5A, RAB5B, RAP1GAP,
RASSF8, SSSCA1, TNFSF12, UBE2E2, VBP1, YWHAH
hsa-let-7a-5p, hsa-miR-107, hsa-miR-128-1-5p, hsa-miR-
142-5p, hsa-miR-148b-5p, hsa-miR-361-5p, hsa-miR-
548s, hsa-miR-616-5p, hsa-miR-647, hsa-miR-766-5p,
hsa-miR-93-5p, hsa-miR-939-5p
Basal SYNE1, LRP2, LRP1, FLNA, RB1,
GOLGA4, SPTAN1, ATN1, CBLB,
CREBBP
GTF2B, MTA1, NR0B1, PBX2, RAB8A, RIT1, S100A8,
SNTB2, TAF15, TCEB2, TXNDC17
hsa-miR-17-5p, hsa-miR-18a-5p, hsa-miR-20a-5p, hsa-
miR-20b-5p, hsa-miR-30c-5p, hsa-miR-3646, hsa-miR-
425-5p, hsa-miR-4778-5p, hsa-miR-6759-5p
Her2 DMD, AKAP9, PRKDC, FBN1,
BRCA2, PIK3R1, HSPG2, PTPN13,
TLN1, NUP98
AKAP5, BIRC5, CLTB, EIF3J, GFRA1, HLA-DPA1,
MAFK, NKX2-1, PDE6G, RBX1, RRAS2, SET, TBPL1,
TERF1
hsa-miR-146a-5p, hsa-miR-148a-5p, hsa-miR-150-5p,
hsa-miR-181b-5p, hsa-miR-24-2-5p, hsa-miR-25-5p, hsa-





PPP3CA, GOLGA2, ETS1, KPNB1,
TUBB2B, AKT1, C8orf33
CHMP4B, GRAP, GZMB, PIM1, PLA2G10, POLDIP2,
PSMC1, PSME3, PTK6, RAC3, RPSA, SCT, SIGIRR, VASP,
WNT1
hsa-miR-1307-5p, hsa-miR-141-5p, hsa-miR-29c-5p, hsa-
miR-3605-5p, hsa-miR-6845-5p
https://doi.org/10.1371/journal.pcbi.1007538.t003
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[65]. The top 20 coding drivers and 17 miRNA drivers for EMT in breast cancer is shown in
Table 4.
Conclusion
Since cancer initialisation and progression are driven by not only coding drivers but also non-
coding drivers, it urgently requires novel and effective methods to discover both coding and
non-coding drivers to elucidate their regulatory mechanism for the development of powerful
cancer treatments. With the fast development of computer science and DNA sequencing tech-
niques, there are multiple computational methods developed to discover cancer drivers. How-
ever, most of the current methods detect coding cancer drivers with mutations while some
genes, which do not contain mutations, regulate driver mutations to develop cancer, and some
non-coding RNAs regulate gene expression and drive cancer.
To overcome the current limitations, we propose the novel method CBNA to discover
cancer drivers based on the gene network information. The aim of CBNA is to integrate vari-
ous types of genomic data such as gene expression, network information, and mutations to
uncover both coding and non-coding drivers (i.e. miRNA drivers). Firstly, based on the gene
expression of cancer patients and the existing databases of gene interactions, we build a net-
work for a condition (i.e. the network for cancer condition). Then, we detect the minimum
node subset which controls the whole network and the ultimate aim is to find critical nodes
of the network. The critical nodes are nodes whose absence increases the size of the mini-
mum node subset controlling the whole network. Because without the critical nodes, we
need to control more nodes to control the whole network, the critical nodes play the central
role of the network and they are likely candidate drivers for the condition of the network (i.e.
cancer condition).
We have applied CBNA to the BRCA dataset to discover breast cancer drivers. Comparing
to the existing methods, our method is more effective in uncovering coding cancer drivers
with mutations as validated by using the CGC. Our method can also identify coding cancer
drivers without mutations as well as miRNA cancer drivers. In addition, the proposed method
can be applied to explore drivers for cancer subtypes and drivers for epithelial to mesenchymal
transition. Take together, we believe the proposed method is a complement for the existing
methods in identifying cancer drivers and it can provide new insights of the molecular regula-
tory mechanisms of cancer initialisation and progression. Thus, it has the potential to contrib-
ute significantly to the design of effective treatment strategies for cancer patients.
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S1 Table. List of coding drivers with mutations. Top 200 predicted coding drivers with
mutations in breast cancer by CBNA.
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Table 4. Top 20 coding and 17 miRNA drivers predicted for EMT in breast cancer.
Coding drivers miRNA drivers
E2F1, FLI1, CREBBP, GATA1, ETS1, EZH2, E2F6,
YWHAG, FOXO1, MBD3, CREB1, TCF3, EBF1, EP300,
YWHAZ, MAZ, FYN, TAF1, SPI1, ATXN1
hsa-miR-128-2-5p, hsa-miR-130a-5p, hsa-miR-141-5p,
hsa-miR-146a-5p, hsa-miR-181a-5p, hsa-miR-18a-5p,
hsa-miR-223-5p, hsa-miR-23a-5p, hsa-miR-31-5p, hsa-
miR-3614-5p, hsa-miR-3648, hsa-miR-4745-5p, hsa-
miR-584-5p, hsa-miR-615-5p, hsa-miR-624-5p, hsa-miR-
663a, hsa-miR-9-5p
https://doi.org/10.1371/journal.pcbi.1007538.t004
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with mutations which are specific to the cancer condition only.
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